These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8791049)

  • 1. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation.
    Schmidt JD; Gibbons RP; Murphy GP; Bartolucci A
    Eur Urol; 1996; 29(4):425-33. PubMed ID: 8791049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project.
    Schmidt JD; Gibbons RP; Murphy GP; Bartolucci A
    Prostate; 1996 Jan; 28(1):51-7. PubMed ID: 8545281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy for localized prostate cancer.
    Schmidt JD; Gibbons RP; Murphy GP; Bartolucci A
    Cancer; 1993 Feb; 71(3 Suppl):1005-13. PubMed ID: 8428323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative clinical trials of the National Prostatic Cancer Project: Protocol 900.
    Schmidt JD
    Prostate; 1984; 5(4):387-99. PubMed ID: 6377283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
    Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
    Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
    Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R; Nordle O; Josefsson K
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
    Cetnar JP; Malkowicz SB; Palmer SC; Wein AJ; Vaughn DJ
    Urology; 2008 May; 71(5):942-6. PubMed ID: 18279928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
    Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression and complications after external beam radiation therapy for carcinoma of prostate.
    Brausi M; Soloway MS
    Urology; 1989 Sep; 34(3):115-9. PubMed ID: 2506686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
    Blanchard P; Faivre L; Lesaunier F; Salem N; Mesgouez-Nebout N; Deniau-Alexandre E; Rolland F; Ferrero JM; Houédé N; Mourey L; Théodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Davin JL; Habibian M; Culine S; Laplanche A; Fizazi K
    Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):85-92. PubMed ID: 26576711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
    Khan MA; Partin AW; Mangold LA; Epstein JI; Walsh PC
    Urology; 2003 Nov; 62(5):866-71. PubMed ID: 14624910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive therapy with interstitial irradiation for prostate cancer.
    deVere White R; Babaian RK; Feldman M; Krane RJ; Olsson CA
    Urology; 1982 Apr; 19(4):395-8. PubMed ID: 6803419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy and adjuvant radioactive gold seed placement: results of treatment at 5 and 10 years for clinical stages A2, B1 and B2 cancer of the prostate.
    Kwon ED; Loening SA; Hawtrey CE
    J Urol; 1991 Mar; 145(3):524-31. PubMed ID: 1997703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression.
    Zincke H; Utz DC; Taylor WF
    J Urol; 1986 Jun; 135(6):1199-205. PubMed ID: 3086572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.